Edition:
United Kingdom

Cancer Genetics Inc (CGIX.OQ)

CGIX.OQ on NASDAQ Stock Exchange Capital Market

1.00USD
23 Apr 2018
Change (% chg)

$-0.10 (-9.09%)
Prev Close
$1.10
Open
$1.05
Day's High
$1.10
Day's Low
$1.00
Volume
66,503
Avg. Vol
97,306
52-wk High
$4.75
52-wk Low
$0.95

Latest Key Developments (Source: Significant Developments)

Cancer Genetics Reports Q4 Loss Per Share Of $0.35
Monday, 2 Apr 2018 

April 2 (Reuters) - Cancer Genetics Inc ::CANCER GENETICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES STRATEGIC BUSINESS UPDATES.Q4 LOSS PER SHARE $0.35.Q4 REVENUE $7.5 MILLION VERSUS I/B/E/S VIEW $9.2 MILLION.Q4 EARNINGS PER SHARE VIEW $-0.11 -- THOMSON REUTERS I/B/E/S.HAS UNDERTAKEN A "COMPREHENSIVE AND EXTENSIVE" REVIEW OF ITS STRATEGY AND ORGANIZATION.ENGAGED RAYMOND JAMES & ASSOCIATES INC AS A FINANCIAL ADVISOR TO ASSIST WITH EVALUATING OPTIONS FOR COMPANY'S STRATEGIC DIRECTION.OPTIONS FOR CO'S STRATEGIC DIRECTION MAY INCLUDE RAISING ADDITIONAL CAPITAL, ACQUISITION OF ANOTHER COMPANY OR SALE OF THE COMPANY.  Full Article

Cancer Genetics Receives Non-Dilutive Funding Of $1.1 Mln
Thursday, 28 Dec 2017 

Dec 28 (Reuters) - Cancer Genetics Inc ::CANCER GENETICS RECEIVES NON-DILUTIVE FUNDING OF $1.1 MILLION THROUGH NEW JERSEY TECHNOLOGY BUSINESS TAX CERTIFICATE TRANSFER (NOL) PROGRAM.CANCER GENETICS INC - ‍RECEIVED $1.1 MILLION IN NET CASH PROCEEDS FROM TRANSFER OF TAX CREDITS.  Full Article

Stonepine Capital Management Reports 5 Percent Passive Stake In Cancer Genetics
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Stonepine Capital Management::STONEPINE CAPITAL MANAGEMENT REPORTS 5 PERCENT PASSIVE STAKE IN CANCER GENETICS INC AS ON DEC 12 - SEC FILING.  Full Article

Cancer Genetics Receives New York State Approval For Oncomine Dx Target Test
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Cancer Genetics Inc ::CANCER GENETICS RECEIVES NEW YORK STATE APPROVAL FOR FDA-APPROVED ONCOMINE DX TARGET TEST BY THERMO FISHER SCIENTIFIC.  Full Article

Cancer Genetics Q3 loss per share $0.15
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Cancer Genetics Inc :Cancer genetics reports record third quarter 2017 revenue and 134% increase in contracted bookings from major biotech and pharmaceutical companies.Q3 loss per share $0.15.Q3 revenue $8.0 million versus i/b/e/s view $7.9 million.Q3 earnings per share view $-0.12 -- Thomson Reuters I/B/E/S.Cancer genetics inc - ‍integration of vivopharm acquisition is on-track and will deliver a full quarter of results and additional revenue in q4 of 2017​.  Full Article

Cancer Genetics to acquire vivoPharm
Monday, 14 Aug 2017 

Aug 14 (Reuters) - Cancer Genetics Inc -:Cancer Genetics announces transformative and accretive acquisition of vivoPharm, a global oncology & immuno-oncology discovery services company.Cancer Genetics Inc - entered into a definitive agreement for cancer genetics to acquire vivoPharm for approximately $12 million usd.Cancer Genetics Inc - Brandt will become president of discovery & early development services at CGI upon completion of acquisition.Cancer Genetics - purchase price is about$12 million, which will include usd $1.2 million in cash and remaining 90% will be shares of CGI common stock.Cancer Genetics Inc - transaction has been approved by boards of directors of both companies.Cancer Genetics Inc - acquisition is expected to be immediately accretive, adding both revenue and income.Cancer Genetics Inc - additionally on August 14, cgi entered into an equity financing arrangement for up to usd $16 million to fund acquisition.Cancer Genetics Inc - initial tranche of funding will be usd $3 million, additional tranches can be accessed by CGI at co's discretion over next 2 years.  Full Article

Cancer Genetics reports Q2 loss per share $0.16
Monday, 14 Aug 2017 

Aug 14 (Reuters) - Cancer Genetics Inc -:Cancer Genetics Inc announces second quarter 2017 financial results, accretive acquisition and capital raise.Q2 loss per share $0.16.Q2 revenue $6.6 million versus I/B/E/S view $8 million.Q2 earnings per share view $-0.15 -- Thomson Reuters I/B/E/S.Cancer genetics inc - ‍acquiring vivopharm for total purchase price of usd $12 million, with proceeds to be 90 percent CGIX stock, and 10 percent cash​.Cancer Genetics Inc - ‍vivopharm deal expected to "immediately" add approximately $5 million revenue.  Full Article

DIA elects Cancer Genetics Inc's John A. (Jay) Roberts as Chairman of board
Thursday, 3 Aug 2017 

Aug 3 (Reuters) - Cancer Genetics Inc ::DIA elects Cancer Genetics Inc's John A(Jay) Roberts as chairman of DIA board of directors.Cancer Genetics Inc - ‍elected John A (Jay) Roberts as chairman of board of directors for one-year term of 2017 - 2018.​.  Full Article

Cancer Genetics files for mixed shelf of up to $100 mln
Thursday, 25 May 2017 

May 25 (Reuters) - Cancer Genetics Inc :Cancer Genetics inc files for mixed shelf of up to $100 million - sec filing.  Full Article

Cancer Genetics partners with Ventana Medical Systems for market access to predictive biomarker test
Monday, 15 May 2017 

May 15 (Reuters) - Cancer Genetics Inc :Cancer Genetics, Inc. Partners with Ventana Medical Systems, Inc., a member of the Roche Group, to ensure market access to predictive biomarker test for new immuno-oncology (io) therapy for advanced bladder cancer.Cancer Genetics - partnered with Ventana Medical Systems to enable rapid patient access to testing following FDA's approval of Roche's Ventana PD-l1 assay.  Full Article

BRIEF-Cancer Genetics’ Unique Tissue Of Origin Test (Too®) Receives Special FDA 510(K) Clearance

* CANCER GENETICS’ UNIQUE TISSUE OF ORIGIN TEST (TOO®) RECEIVES SPECIAL FDA 510(K) CLEARANCE